Accordingly, the pretreatment of primary CLL B cells with ibrutinib, a potent inhibitor of BTK, prevented the stabilization of β-catenin, indicating that in the presence of stromal cells, BTK is involved in β-catenin stabilization (Figure 4A). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.